{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:29:09Z","timestamp":1792772949073,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01237-9","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:03:54Z","timestamp":1789376634000},"page":"1628-1642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7122","authenticated-orcid":false,"given":"Silvia","family":"Marsoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Montagut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-4240","authenticated-orcid":false,"given":"Luca","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-1655","authenticated-orcid":false,"given":"Noelia","family":"Tarazona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8846-8959","authenticated-orcid":false,"given":"Mario","family":"Mandal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-5097","authenticated-orcid":false,"given":"Cristina","family":"Santos Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Luraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Segu\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Maddalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Taglialatela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2143-0697","authenticated-orcid":false,"given":"Marta","family":"Guix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vettore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Isella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-1555","authenticated-orcid":false,"given":"Giovanni","family":"Crisafulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-2158","authenticated-orcid":false,"given":"Giorgio","family":"Patelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-2438","authenticated-orcid":false,"given":"Enzo","family":"Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3806-3691","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-2846","authenticated-orcid":false,"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1237_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1237_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s, G. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291\u20131305 (2020).","journal-title":"Ann. Oncol."},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 21, 1620\u20131629 (2020).","journal-title":"Lancet Oncol."},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey, A. et al. Duration of adjuvant chemotherapy for stage III colon cancer. N. Engl. J. Med. 378, 1177\u20131188 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1237_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.19.00281","volume":"37","author":"C Lieu","year":"2019","unstructured":"Lieu, C. et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J. Clin. Oncol. 37, 1436\u20131447 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR6","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1200\/JCO.2017.76.2187","volume":"36","author":"A Sobrero","year":"2018","unstructured":"Sobrero, A. et al. FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the italian three or six colon adjuvant trial. J. Clin. Oncol. 36, 1478\u20131485 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1001\/jamaoncol.2019.2572","volume":"5","author":"T Yoshino","year":"2019","unstructured":"Yoshino, T. et al. Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial. JAMA Oncol. 5, 1574\u20131581 (2019).","journal-title":"JAMA Oncol."},{"key":"1237_CR8","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.21.02628","volume":"40","author":"T Yoshino","year":"2022","unstructured":"Yoshino, T. et al. Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial. J. Clin. Oncol. 40, 3419\u20133429 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR9","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1237_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","volume":"5","author":"T Reinert","year":"2019","unstructured":"Reinert, T. et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectalcancer. JAMA Oncol. 5, 1124\u20131131 (2019).","journal-title":"JAMA Oncol."},{"key":"1237_CR11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","volume":"5","author":"J Tie","year":"2019","unstructured":"Tie, J. et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5, 1710\u20131717 (2019).","journal-title":"JAMA Oncol."},{"key":"1237_CR12","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","volume":"30","author":"N Tarazona","year":"2019","unstructured":"Tarazona, N. et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann. Oncol. 30, 1804\u20131812 (2019).","journal-title":"Ann. Oncol."},{"key":"1237_CR13","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin. Cancer Res. 27, 5586\u20135594 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1237_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","volume":"28","author":"TV Henriksen","year":"2022","unstructured":"Henriksen, T. V. et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin. Cancer Res. 28, 507\u2013517 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1237_CR15","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin. Cancer Res. 30, 4377\u20134387 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1237_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"1237_CR17","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","volume":"30","author":"Y Nakamura","year":"2024","unstructured":"Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272\u20133283 (2024).","journal-title":"Nat. Med."},{"key":"1237_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/s43018-025-00960-z","volume":"6","author":"J Mart\u00edn-Arana","year":"2025","unstructured":"Mart\u00edn-Arana, J. et al. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Nat. Cancer 6, 1000\u20131016 (2025).","journal-title":"Nat. Cancer"},{"key":"1237_CR19","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.24.00648","volume":"43","author":"J Taieb","year":"2025","unstructured":"Taieb, J. et al. Combined analyses of circulating tumor DNA and immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France\/HORG-IDEA-Greece trials. J. Clin. Oncol. 43, 1564\u20131577 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR20","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1200\/JCO-25-02086","volume":"44","author":"FA Sinicrope","year":"2026","unstructured":"Sinicrope, F. A. et al. Tissue-free circulating tumor dna assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147). J. Clin. Oncol. 44, 1401\u20131415 https:\/\/doi.org\/10.1200\/JCO-25-02086 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR21","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S1470-2045(25)00542-X","volume":"26","author":"A Amatu","year":"2025","unstructured":"Amatu, A. et al. Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 26, 1612\u20131625 (2025).","journal-title":"Lancet Oncol."},{"key":"1237_CR22","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261\u20132272 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1237_CR23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/s41591-025-03579-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509\u20131518 (2025).","journal-title":"Nat. Med."},{"key":"1237_CR24","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41591-025-04030-w","volume":"31","author":"J Tie","year":"2025","unstructured":"Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2\/3 DYNAMIC-III trial. Nat. Med. 31, 4291\u20134300 (2025).","journal-title":"Nat. Med."},{"key":"1237_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"key":"1237_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.annonc.2024.12.006","volume":"36","author":"B Mart\u00ednez-Castedo","year":"2025","unstructured":"Mart\u00ednez-Castedo, B. et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Ann. Oncol. 36, 263\u2013276 (2025).","journal-title":"Ann. Oncol."},{"key":"1237_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"1237_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrc.2016.126","volume":"17","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79\u201392 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1237_CR29","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamaoncol.2025.3760","volume":"11","author":"A Pastorino","year":"2025","unstructured":"Pastorino, A. et al. The definition of cure in colon cancer: a pooled analysis of 15 randomized clinical trials. JAMA Oncol. 11, 1440\u20131448 (2025).","journal-title":"JAMA Oncol."},{"key":"1237_CR30","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1093\/annonc\/mdw404","volume":"27","author":"S Lonardi","year":"2016","unstructured":"Lonardi, S. et al. Phase III trial comparing 3\u20136 months of adjuvant FOLFOX4\/XELOX in stage II\u2013III colon cancer: safety and compliance in the TOSCA trial. Ann. Oncol. 27, 2074\u20132081 (2016).","journal-title":"Ann. Oncol."},{"key":"1237_CR31","doi-asserted-by":"publisher","first-page":"e2500142","DOI":"10.1200\/PO-25-00142","volume":"9","author":"AJ Pellatt","year":"2025","unstructured":"Pellatt, A. J. et al. Phase II trial of TAS-102 in colorectal cancer patients with circulating tumor DNA-defined minimal residual disease after adjuvant therapy: INTERCEPT-TT. JCO Precis. Oncol. 9, e2500142 https:\/\/doi.org\/10.1200\/PO-25-00142 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1237_CR32","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-026-04428-0","volume":"32","author":"H Bando","year":"2026","unstructured":"Bando, H. et al. Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial. Nat. Med. 32, 2473\u20132480 https:\/\/doi.org\/10.1038\/s41591-026-04428-0 (2026).","journal-title":"Nat. Med."},{"key":"1237_CR33","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","volume":"27","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117\u20133125 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR34","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","volume":"25","author":"LB Saltz","year":"2007","unstructured":"Saltz, L. B. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25, 3456\u20133461 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-10","volume":"9","author":"CA Papadimitriou","year":"2011","unstructured":"Papadimitriou, C. A. et al. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med. 9, 10 (2011).","journal-title":"BMC Med."},{"key":"1237_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00535","volume":"6","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis. Oncol. 6, e2100535 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1237_CR37","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","volume":"30","author":"S Slater","year":"2024","unstructured":"Slater, S. et al. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC part B study. Clin. Cancer Res. 30, 3459\u20133469 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1237_CR38","doi-asserted-by":"publisher","first-page":"105496","DOI":"10.1016\/j.esmoop.2025.105496","volume":"10","author":"V Dapr\u00e0","year":"2025","unstructured":"Dapr\u00e0, V. et al. Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset. ESMO Open 10, 105496 (2025).","journal-title":"ESMO Open"},{"key":"1237_CR39","doi-asserted-by":"publisher","first-page":"CT214","DOI":"10.1158\/1538-7445.AM2019-CT214","volume":"79","author":"L Lazzari","year":"2019","unstructured":"Lazzari, L. et al. Abstract CT214: AlfaOmega\u2014a master protocol empowering precision research in colorectal cancer. Cancer Res. 79, CT214\u2013CT214 (2019).","journal-title":"Cancer Res."},{"key":"1237_CR40","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.2025.43.16_suppl.3604","volume":"43","author":"I Franken","year":"2025","unstructured":"Franken, I. et al. Complementary value of a digital pathology biomarker to post-surgery circulating tumor DNA in risk stratification of stage III colon cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 43, 3604\u20133604 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105935","volume":"11","author":"IA Franken","year":"2026","unstructured":"Franken, I. A. et al. Added value of tumor\u2013stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy. ESMO Open 11, 105935 (2026).","journal-title":"ESMO Open"},{"key":"1237_CR42","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1016\/j.annonc.2024.08.071","volume":"35","author":"E Medico","year":"2024","unstructured":"Medico, E. et al. 63O transcriptional features of stage IIT4N0\/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial. Ann. Oncol. 35, S238 (2024).","journal-title":"Ann. Oncol."},{"key":"1237_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36334-1","volume":"14","author":"J Linares","year":"2023","unstructured":"Linares, J. et al. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nat. Commun. 14, 746 (2023).","journal-title":"Nat. Commun."},{"key":"1237_CR44","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1200\/JCO.23.02262","volume":"43","author":"C Gallois","year":"2025","unstructured":"Gallois, C. et al. Prognostic models from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA-France trials. J. Clin. Oncol. 43, 1765\u20131776 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR45","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-24-0556","volume":"16","author":"M Avolio","year":"2026","unstructured":"Avolio, M. et al. The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancer. Cancer Discov. 16, 270\u2013295 (2026).","journal-title":"Cancer Discov."},{"key":"1237_CR46","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.annonc.2020.03.310","volume":"31","author":"F Pag\u00e8s","year":"2020","unstructured":"Pag\u00e8s, F. et al. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study. Ann. Oncol. 31, 921\u2013929 (2020).","journal-title":"Ann. Oncol."},{"key":"1237_CR47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/jclinpath-2020-207309","volume":"74","author":"K Wilkinson","year":"2021","unstructured":"Wilkinson, K. et al. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer. J. Clin. Pathol. 74, 625\u2013634 (2021).","journal-title":"J. Clin. Pathol."},{"key":"1237_CR48","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.annonc.2024.05.037","volume":"35","author":"G Mauri","year":"2024","unstructured":"Mauri, G. et al. 26P response in patient-derived models recapitulates circulating tumor DNA clearance of matched colon cancer patients after adjuvant treatment in the PEGASUS trial. Ann. Oncol. 35, S13\u2013S14 (2024).","journal-title":"Ann. Oncol."},{"key":"1237_CR49","doi-asserted-by":"publisher","first-page":"TPS364","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3647","volume":"43","author":"CO Montagut","year":"2025","unstructured":"Montagut, C. O. et al. A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (pts): the SAGITTARIUS trial. J. Clin. Oncol. 43, TPS364 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1237_CR50","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell, S. et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ 389, e081123 (2025).","journal-title":"BMJ"},{"key":"1237_CR51","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1158\/1078-0432.CCR-23-3660","volume":"30","author":"AR Parikh","year":"2024","unstructured":"Parikh, A. R. et al. Minimal residual disease using a plasma-only circulating tumor DNA assay to predict recurrence of metastatic colorectal cancer following curative intent treatment. Clin. Cancer Res. 30, 2964\u20132973 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1237_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2020.02.009","volume":"130","author":"R Cohen","year":"2020","unstructured":"Cohen, R. et al. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: results of the DATECAN initiative. Eur. J. Cancer 130, 63\u201371 (2020).","journal-title":"Eur. J. Cancer"},{"key":"1237_CR53","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41592-024-02405-4","volume":"21","author":"CF Kurz","year":"2024","unstructured":"Kurz, C. F., Krzywinski, M. & Altman, N. Propensity score matching. Nat. Methods 21, 1770\u20131772 (2024).","journal-title":"Nat. Methods"},{"key":"1237_CR54","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis, A., Sackett, D. L. & Roberts, R. S. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318, 1728\u20131733 (1988).","journal-title":"N. Engl. J. Med."},{"key":"1237_CR55","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman, D. G. Confidence intervals for the number needed to treat. Br. Med. J. 317, 1309\u20131312 (1998).","journal-title":"Br. Med. J."},{"key":"1237_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14892-x","volume":"7","author":"Y Xiong","year":"2017","unstructured":"Xiong, Y. et al. A Comparison of mRNA sequencing with random primed and 3\u2032-directed libraries. Sci. Rep. 7, 14626 (2017).","journal-title":"Sci. Rep."},{"key":"1237_CR57","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/bioinformatics\/btx668","volume":"34","author":"K Kri\u017eanovi\u0107","year":"2018","unstructured":"Kri\u017eanovi\u0107, K., Echchiki, A., Roux, J. & \u0160iki\u0107, M. Evaluation of tools for long read RNA-seq splice-aware alignment. Bioinformatics 34, 748\u2013754 (2018).","journal-title":"Bioinformatics"},{"key":"1237_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1237_CR59","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1237_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16747-x","volume":"7","author":"PW Eide","year":"2017","unstructured":"Eide, P. W., Bruun, J., Lothe, R. A. & Sveen, A. CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci. Rep. 7, 16618 (2017).","journal-title":"Sci. Rep."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01237-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:01:59Z","timestamp":1792764119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01237-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":60,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01237-9","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. received institutional research funding from MSD, AstraZeneca and Illumina. C.M. received advisory board or speaker fees from Amgen, Bayer, BMS, Guardant Health, Hoffman-La Roche, Lilly, Merck Serono, MSD, Pfizer, Pierre-Fabre, Sanofi, Servier and Takeda. A.S.-B. is an advisory board member for Amgen, Bayer, Servier, Pierre-Fabre and Takeda. F.P. received institutional research funding from Lilly, Bristol-Myers Squibb, Incyte, AstraZeneca, Amgen, Agenus, Rottapharm, Johnson & Johnson, GSK and Tempus; personal honoraria as an invited speaker from BeOne, Daiichi-Sankyo, Seagen, Astellas, Ipsen, AstraZeneca, Servier, Bayer, Takeda, Johnson & Johnson, Bristol-Myers Squibb, MSD, Amgen, Merck Serono, Pierre-Fabre and Incyte; advisory or consultancy fees from Bristol-Myers Squibb, MSD, Amgen, Pierre-Fabre, Johnson & Johnson, Servier, Bayer, Takeda, Astellas, GSK, Daiichi-Sankyo, Pfizer, BeOne, Jazz Pharmaceuticals, Incyte, Rottapharm, Merck Serono, Italfarmaco, Gilead, AstraZeneca, Agenus and Revolution Medicine; and travel expenses from Amgen, Merck Serono, Pierre-Fabre, Servier, Astellas, Incyte and Johnson & Johnson. F.B. reports participation on an advisory board for Novartis, Teysuno and Takeda, and personal honoraria as invited speaker from Eli-Lilly, MSD, Bayer, BMS, Pierre-Fabre and AstraZeneca. M.G.Z. is an advisory board member for GlaxoSmithKline. N.T. declares advisory board or speaker fees from Merck Serono, Servier, Pfizer, Natera and Guardant Health. M.M. received honoraria from Bristol-Myers Squibb, LEO Pharma, MSD, Novartis, Pierre-Fabre, Regeneron and Sanofi; advisory board or consulting fees from Bristol-Myers Squibb, LEO Pharma, MSD, Novartis, Pierre-Fabre and Regeneron; and institutional research funding from Novartis. S.T. received advisory board or speaker fees from AstraZeneca, Seagen and Takeda. E.E. received advisory board or speaker fees from Amgen, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Cure Teq AG, Hoffman-La Roche, Janssen, Lilly, Medscape, Merck Serono, MSD, Novartis, Organon, Pfizer, Pierre-Fabre, Repare Therapeutics Inc., RIN Institute Inc., Sanofi, Seagen International, GmbH, Servier and Takeda. C.S.V. received speakers\u2019 bureau expenses from AMGEN and travel funding from Amgen and Merck. P.L. is currently an employee of AstraZeneca. D.C. received consulting fees from Foundation Medicine and Merck KgA, and travel support by Sanofi, Bristol-Myers Squibb and Merck KgA. J.V. reports personal fees from Merck, Amgen, MSD, Novartis, Bristol-Myers Squibb and Pierre-Fabre outside the submitted work. K.B. is an advisory board member for Amgen. F.M. declares honoraria from Pierre-Fabre and Servier; institutional research grants from Incyte; and travel grants from Amgen and Pierre-Fabre. A.B. reports receipt of grants or research supports from Neophore, AstraZeneca and Boehringer Ingelheim, and honoraria or consultation fees from Guardant Health; is a stock shareholder of Neophore and Kither Biotech; and participates on an advisory board for Neophore. A.C. declares institutional research funding from Genentech, Merck Serono, Bristol-Myers Squibb, MSD, Roche, Beigene, Bayer, Servier, Lilly, Natera, Novartis, Takeda, Astellas and Fibrogen, and advisory board or speaker fees from Merck Serono, Roche, Servier, Takeda and Astellas. V.T. declares honoraria for lectures at AstraZeneca. J.T. reports personal financial interest in the form of a scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai, Daiichi-Sankyo, F. Hoffmann-La Roche, Genentech, Johnson & Johnson\/Janssen, Lilly, Menarini, Merus, MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre-Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics; and stocks from Alentis Therapeutics, Oniria Therapeutics, 1TRIALSP and Pangaea Oncology. S.S. is scientific advisory board member for Agenus, AstraZeneca, Bayer, Bristol-Myers Squibb, CheckmAb, Daiichi-Sankyo, GlaxoSmithKline, MSD, Merck, Novartis, Pierre-Fabre, Pfizer, Seagen and T-One Therapeutics. S.L. reports personal honoraria as invited speaker from Amgen, Bristol-Myers Squibb, Incyte, GSK, Lilly, Merck Serono, MSD, Pierre-Fabre, Roche and Servier, and participates on advisory boards for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Helion, GSK, Incyte, Lilly, Merck Serono, MSD, Servier, Takeda, Rottapharm, Beigene, Fosum Pharma and Nimbus Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}